Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (not Ocugen, Inc.) reports corporate governance changes effective February 22, 2019. The report date is February 25, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes.
Material Changes
- Resignation: Garheng Kong, M.D., Ph.D., resigned as Chairman and member of the Board of Directors and all committees effective February 22, 2019.
- Reason: Dr. Kong resigned to devote full-time efforts to other commitments. The filing explicitly states there was no disagreement with the Company's operations, financials, policies, or procedures.
- Board Composition: The number of directors was reduced from eight to seven.
- Appointments: Joshua Baltzell was appointed as the new Chairman of the Board and Chairman of the Nominating/Corporate Governance Committee effective February 22, 2019.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to thanking Dr. Kong for his service since 2012 and confirming Mr. Baltzell's independence status.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and committee assignments following the reduction to seven members.
- Confirm Joshua Baltzell's background and independence status as the new Chairman.
- Review subsequent filings to ensure no undisclosed disagreements regarding the resignation of Dr. Kong.